Product Description
Mechanisms of Action: Global Transcription Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clavis Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Myeloid Leukemia|Leukemia
Phase 2: Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Melanoma|Leukemia|Ovarian Cancer|Colorectal Cancer
Phase 1: Healthy Volunteers|Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-008518-38 | P2 |
Terminated |
Leukemia |
2013-05-07 |
|
CP-4055 | P1 |
Completed |
Leukemia |
2013-05-01 |
|
CP4055-205 | P2 |
Completed |
Acute Myeloid Leukemia |
2013-05-01 |
|
CP4055-110 | P1 |
Completed |
Healthy Volunteers |
2013-02-01 |